{"contentid": 487925, "importid": NaN, "name": "Safer sleep drug could break new ground in Europe", "introduction": "Swiss biotech Idorsia has submitted for European approval for daridorexant, an investigational dual orexin receptor antagonist, in the treatment of insomnia.", "content": "<p>Swiss biotech Idorsia (SIX: IDIA) has submitted for European approval for daridorexant, an investigational dual orexin receptor antagonist, in the treatment of insomnia.</p>\n<p>The Allschwil-based firm believes the drug, which works by blocking the activity of the neuropeptide orexin, could help extend sleep and improve daytime functioning for adults who suffer from the condition.</p>\n<p>Importantly, the company hopes to improve on the safety profile of existing options, a key aspect of insomnia research given risks stemming from impairment to daytime functioning.</p>\n<p>Merck &amp; Co (NYSE: MRK) and Eisai (TYO: 4523) already market orexin blockers - Belsomra (suvorexant) and Dayvigo (lemborexant) - but both have box warnings regarding the impact on daytime functioning, including the ability to drive motor vehicles.</p>\n<p>Neither are currently approved in Europe, providing Idorsia with the chance to make a breakthrough in the region.</p>\n<p>Seltorexant, another candidate in this class under development by Johnson &amp; Johnson&rsquo;s (NYSE: JNJ) pharma arm Janssen and Minerva&nbsp;Neurosciences, is still in mid-stage development.</p>\n<h2>Daridorexant development</h2>\n<p>Idorsia&rsquo;s lead compound, daridorexant, now boasts positive results from two pivotal studies, and the company is actively preparing for launch, in anticipation of regulatory approval.</p>\n<p>In late 2020, the firm conducted a rights offering to raise over $600 million, money which is earmarked for regulatory activities and commercial launch of the product.</p>\n<p>The firm has already submitted to the US FDA for approval, and the company anticipates launching in the US in the first half of 2022 if all goes well.</p>\n<p>Chief executive Jean-Paul Clozel said the submission was &ldquo;an indication of our commitment to transform the treatment of insomnia around the globe.&rdquo;</p>\n<p>He added: &ldquo;Most of the current treatment options are acting on the brain in a non-specific way, with restrictions due to safety concerns. This is the first European marketing application for a dual orexin receptor antagonist and, if approved, daridorexant would be the first insomnia treatment acting by a novel mechanism in decades.&rdquo;</p>", "date": "2021-03-03 10:04:00", "meta_title": NaN, "meta_keywords": "orexin, insomnia, daridorexant, treatment, approval, Idorsia, submitted, receptor, dual, antagonist, European, sleep, drug, Europe, ground, break, Safer", "meta_description": "Swiss biotech Idorsia has submitted for European approval for daridorexant, an investigational dual orexin receptor antagonist, in the treatment of insomnia.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-03 09:39:00", "updated": "2021-03-03 18:00:36", "access": NaN, "url": "https://www.thepharmaletter.com/article/safer-sleep-drug-could-break-new-ground-in-europe", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "idorsia_large-1-.png", "image2id": "idorsia_small-1-.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Neurological", "topic_tag": "European Medicines Agency, Focus On, Regulation, Research", "geography_tag": "Japan, Switzerland, USA", "company_tag": "Eisai, Idorsia, Merck & Co", "drug_tag": "Belsomra, daridorexant, Dayvigo", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-03 10:04:00"}